Singapore markets open in 1 hour 33 minutes
Straits Times Index
3,225.35 +23.46 (+0.73%) S&P 500
3,923.68 -165.17 (-4.04%) Dow
31,490.07 -1,164.52 (-3.57%) Nasdaq
11,418.15 -566.37 (-4.73%) BTC-USD
28,939.01 -1,560.73 (-5.12%) CMC Crypto 200
650.57 -20.11 (-3.00%)
Eli Lilly and Company (LLY)
NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
At close: 04:04PM EDT
After hours:
| Previous close | 301.40 |
| Open | 300.00 |
| Bid | 293.64 x 800 |
| Ask | 295.69 x 1100 |
| Day's range | 294.03 - 302.43 |
| 52-week range | 193.11 - 314.00 |
| Volume | |
| Avg. volume | 2,967,843 |
| Market cap | 280.478B |
| Beta (5Y monthly) | 0.43 |
| PE ratio (TTM) | 43.87 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.92 (1.34%) |
| Ex-dividend date | 13 May 2022 |
| 1y target est | N/A |
- Zacks
AstraZeneca (AZN) Inks Deal to Develop COVID-19 Antibodies
AstraZeneca (AZN) partners with a U.K.-based biotech company to develop monoclonal antibodies targeting the COVID-causing virus.
- Motley Fool
Why Eli Lilly Stock Climbed Today
Shares of Eli Lilly (NYSE: LLY) rose on Monday after the U.S. Food and Drug Administration (FDA) approved the pharmaceutical giant's new diabetes treatment, tirzepatide. As of 1:50 p.m. ET, Eli Lilly's stock price was up more than 3%. A phase 3 clinical trial showed tirzepatide to reduce A1C -- a key measure of average blood sugar levels -- better than existing treatment options.
- Zacks
Lilly's (LLY) Diabetes Treatment Tirzepatide Gets FDA Nod
Lilly's (LLY) Mounjaro (tirzepatide) is a novel diabetes treatment, which has shown impressive blood sugar reductions and weight loss in a broad range of type II diabetes patients in the SURPASS studies.
© 2022 Yahoo. All rights reserved.
